Association of Serum Lactate Level with Severity of PreEclampsia and Maternal Complications: An Observational Study
- 1. Senior Resident, Department of Obstetrics and Gynaecology, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar
- 2. Senior Resident, Department of Surgery, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar
- 3. Associate Professor, Department of Obstetrics and Gynaecology, Sri Krishna Medical College and Hospital, Muzaffarpur, Bihar
Description
Background: Pregnancy-related hypertensive problems are the most prevalent medical conditions. It increases mortality and morbidity rates for pregnant women and newborns. Incidence ranges from 5 to 10%. Complications can be minimised by identifying high risk patients and closely monitoring them. A helpful biochemical marker called lactate dehydrogenase can be used to assess maternal complications like disseminated intravascular coagulation (DIC), HELLP syndrome (haemolysis, elevated liver enzymes, and lowered platelets), pulmonary edema, renal failure, and foetal complications like foetal growth restriction (FGR) with an APGAR score ≤7 at five minutes and NICU admissions. Estimating serum Lactate dehydrogenase (LDH) levels in pre-eclampsia patients and examining the relationship between elevated LDH levels and maternal and foetal outcomes were the two main goals of this study. Methods: It was a prospective study from March 2022 to August 2022 at Sri Krishna Medical College and Hospitals, Muzaffarpur, Bihar. Results: Higher serum LDH concentrations were associated with an increased risk of maternal and foetal problems. The incidence of HELLP syndrome, DIC, and pulmonary edema was statistically significant when serum LDH was more than 600 IU/l. It also showed a p value of <0.001 correlation between lower platelets and higher creatinine levels. Apgar scores below 7 at 5 minutes and FGR NICU hospitalisation were considered statistically severe foetal problems. LDH levels rose in correlation with serum creatinine and liver enzymes. Conclusions: Raised LDH levels increase maternal and foetal problems, and it can be utilised as a biochemical marker to improve outcomes.
Abstract (English)
Background: Pregnancy-related hypertensive problems are the most prevalent medical conditions. It increases mortality and morbidity rates for pregnant women and newborns. Incidence ranges from 5 to 10%. Complications can be minimised by identifying high risk patients and closely monitoring them. A helpful biochemical marker called lactate dehydrogenase can be used to assess maternal complications like disseminated intravascular coagulation (DIC), HELLP syndrome (haemolysis, elevated liver enzymes, and lowered platelets), pulmonary edema, renal failure, and foetal complications like foetal growth restriction (FGR) with an APGAR score ≤7 at five minutes and NICU admissions. Estimating serum Lactate dehydrogenase (LDH) levels in pre-eclampsia patients and examining the relationship between elevated LDH levels and maternal and foetal outcomes were the two main goals of this study. Methods: It was a prospective study from March 2022 to August 2022 at Sri Krishna Medical College and Hospitals, Muzaffarpur, Bihar. Results: Higher serum LDH concentrations were associated with an increased risk of maternal and foetal problems. The incidence of HELLP syndrome, DIC, and pulmonary edema was statistically significant when serum LDH was more than 600 IU/l. It also showed a p value of <0.001 correlation between lower platelets and higher creatinine levels. Apgar scores below 7 at 5 minutes and FGR NICU hospitalisation were considered statistically severe foetal problems. LDH levels rose in correlation with serum creatinine and liver enzymes. Conclusions: Raised LDH levels increase maternal and foetal problems, and it can be utilised as a biochemical marker to improve outcomes.
Files
IJPCR,Vol14,Issue10,Article59.pdf
Files
(294.1 kB)
| Name | Size | Download all |
|---|---|---|
|
md5:834d2f4ee3fd40b3455fb208eb398c67
|
294.1 kB | Preview Download |
Additional details
Dates
- Accepted
-
2022-10-09
Software
- Repository URL
- https://impactfactor.org/PDF/IJPCR/14/IJPCR,Vol14,Issue10,Article59.pdf
- Development Status
- Active
References
- 1. Marlene MC. William's Obstetrics. 24th ed. Doctorlib; 2014: 728-770. 2. Vinitha PM, Chellatamizh M, Padmanaban S. Role of serum LDH in pre-eclampsia as a prognostic factor- a cross sectional case control study in tertiary care hospital. Int J Repord Contracept Obstet Gynaecol. 2017; 6:595-8. 3. Hak J, Nisa NU, Gupta S. LDH levels in pregnancy and its association with severity of the disease and fetomaternal outcome in pre-eclampsia and eclampsia. JK Sci. 2015;17(3):110-3.4. Gupte S, Wagh G. Preeclampsiaeclampsia. J Obstet Gynaecol India. 2014;64(1):4-13. 5. Petla LT, Chikkala R, Ratnakar KS, Kodati V, Sritharan V. Biomarkers for the management of pre-eclampsia in pregnant women. Indian J Med Res. 2013;138(1):60-7. 6. He S, Bremme K, Kallner A, Blombäck M. Increased concentrations of lactate dehydrogenase in pregnancy with preeclampsia: a predictor for the birth of small-for-gestational-age infants. Gynecol Obstet Invest. 1995;39(4):234-8. 7. Qublan HS, Ammarin V, Bataineh O, Shraideh Z, Tahat Y, Awamleh I, Khreisat B, et al. Lactic dehydrogenase as a biochemical marker of adverse pregnancy outcome in severe preeclampsia. Med Sci Monit. 2005;11(8):393-7. 8. Sharma U, Hariharan C. Maternal and outcome in PIH patients in relation with serum LDH levels. IOSR J Dent Med Sci. 2017;16(1):1-4. 9. Bera S, Gupta S, Saha S, Kunti S, Biswas S, Ghosh D. Study of Liver Enzymes Especially Lactate Dehydrogenase to Predict Foetal Outcome in Pregnancy Induced Hypertension. Scholar's J Applied Med Sci. 2014;2(5):1569-72. 10. Walker JJ. Pre-eclampsia. Lancet. 2000;356(9237):1260-5. 11. Dave A, Maru L, Jain A. LDH (Lactate Dehydrogenase): A Biochemical Marker for the Prediction of Adverse Outcomes in Pre-eclampsia and Eclampsia. J Obstet Gynaecol India. 2016;66(1):23-9. 12. Jaiswar SP, Gupta A, Sachan R, Natu SN, Shaili M. Lactic dehydrogenase: a biochemical marker for preeclampsiaeclampsia. J Obstet Gynaecol India. 2011;61(6):645-8. 13. Doddamani UG, Doddamani GB. Perinatal Outcome in Pre-Eclampsia: A Prospective Study. Sch J App Med Sci. 2014;2(1):291-3. 14. Aziz R, Mahboob T. Relation between preeclampsia and cardiac enzymes. Atheroscl J. 2008;4(1):29-32. 15. Umastayasri Y, Vani I, Shamita P. Role of LDH (Lactate Dehydrogenase) in preeclampsia-eclampsia as a prognostic marker: An observational study. Int Arch Integrat Med. 2015;2(9):88-93. 16. Hazari NR, Hatolkar VS, Munde SM. Study of Serum Hepatic Enzymes in Preeclampsia. Int J Current Med App Sci. 2014;2(1):1-8. 17. Agrawal S, Walia GK. Prevalence and risk factors for Preeclampsia in Indian women: a national cross-sectional study. South Asia network for chronic disease. Public Health Found India. 2014;1-23. 18. Hall DR, Odendaal HJ, Kirsten GF, Smith J, Grové D. Expectant management of early onset, severe preeclampsia: perinatal outcome. BJOG. 2000;107(10):1258-64. 19. Seed PT, Chappell LC, Black MA, Poppe KK, Hwang YC, Kasabov N, et al. Prediction of preeclampsia and delivery of small for gestational age babies based on a combination of clinical risk factors in high-risk women. Hypertens Pregnancy. 2011;30(1):58-73. 20. Townsend R, Brien P, Khalil A. Current best practice in the management of hypertensive disorders in pregnancy. Integr Blood Press Control. 2016; 9:79-94.